Omeros (OMER)
(Delayed Data from NSDQ)
$3.36 USD
+0.04 (1.20%)
Updated May 31, 2024 04:00 PM ET
After-Market: $3.36 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
B Value A Growth D Momentum A VGM
Brokerage Reports
Omeros Corporation [OMER]
Reports for Purchase
Showing records 341 - 360 ( 423 total )
Company: Omeros Corporation
Industry: Medical - Products
Company: Omeros Corporation
Industry: Medical - Products
Ophthalmology Expert''s Insights Support Attractive Risk:Reward For Second OMS302 Phase 3 Trial In Our View. Data Release in H2:12.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
IND Filed for OMS824 (PDE10 Inhibitor for Cognitive Disorders) with Phase 1 Data Anticipated by Year-end; Reiterate OUTPERFORM and $19 FV
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
Movie Rental and Exhibitor Biweekly Newsletter-May 21 - June 3
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
Company: Omeros Corporation
Industry: Medical - Products
Company: Omeros Corporation
Industry: Medical - Products
Q1 Financials Uneventful, but Cash Runway Lasts Through Transforming Catalyst
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
Company: Omeros Corporation
Industry: Medical - Products
Company: Omeros Corporation
Industry: Medical - Products
LIFE SCIENCES-The Week Ahead in Life Sciences - Upcoming Events for the Week of May 6
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
Initiation of Enrollment in Second OMS302 Phase 3 Trial Sets Timeline for Clinical Data Release in H2:12. Reiterate OUTPERFORM and $20 FV
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
Company: Omeros Corporation
Industry: Medical - Products
Issuance of Additional OMS302 Patent Further Strengthens Intellectual Property. Reiterate OUTPERFORM and $20 FV.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
Increasing Our Projections For OMS302 Due To Strong Clinical Profile And Increasing Procedure Volumes. Raising FV to $20 and Reiterate OUTPERFORM.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
`OMS302 Hits Primary and Secondary Endpoints in Phase 3 Trial.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
Pivotal Eye Data Achieved All Endpoints - Raising Target Price
Provider: RODMAN & RENSHAW, CO.
Analyst: PIROS E
Company: Omeros Corporation
Industry: Medical - Products
Pivotal Eye Data Achieved All Endpoints - Raising Target Price
Provider: RODMAN & RENSHAW, CO.
Analyst: PIROS E
Company: Omeros Corporation
Industry: Medical - Products
Company: Omeros Corporation
Industry: Medical - Products
Receives Government Funding for Development of a Non-Addictive Analgesic.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
OMS302 Design Optimized To Increase Probability of Success. Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L